Abbreviated Name

BRL: PNNL

Lead Investigator

Liu, Tao — Pacific Northwest National Laboratory

Coordinating Investigator

No coordinating investigator

Involved Investigators

• Liu, Tao — Pacific Northwest National Laboratory

Abstact

Aims

Stage I: A feasibility study – comparing a limited number (5) of available scFv library derived antibodies (in a number of antibody formats such as scFv, Fab and IgG) and commercially available monoclonal antibodies directed at the same cancer-associated antigens on the same slide with appropriate controls. This will involve identification, development, and production, of 20 monoclonal antibody pairs specific for 5 antigens with subsequent utilization demonstrated in a micro ELISA assay. The antibody pairs are represented by one detection antibody and 4 capture antibodies derived as affinity matured subclones directed against the same epitope. The capture antibodies will have affinities ranging from 100 nM to 100 pM. Stage II: Extension of the phase I study to ~50 antigens and controls chosen on the basis of potential as cancer biomarkers. In this stage PNNL will: (a) train selected EDRN investigators in the use of the microarray platform, and (b) print a large number of microarrays (1500 slides) for analytical and clinical validation studies.

Analytic Method

Biomarkers

• No biomarkers available at this time for this protocol

Data Collections

• No data available at this time for this protocol

 Team Project

Protocol ID

231

Protocol Type

Single

Field of Research

Other, Specify

Collaborative Group

(No collaborative group)

Cancer Types

• (No cancer types specified)